Cerus Corporation (CERS)

NASDAQ: CERS · Real-Time Price · USD
1.210
-0.030 (-2.42%)
Aug 8, 2025, 4:00 PM - Market closed
-2.42%
Market Cap231.96M
Revenue (ttm)192.51M
Net Income (ttm)-18.88M
Shares Out 191.70M
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume761,690
Open1.250
Previous Close1.240
Day's Range1.210 - 1.250
52-Week Range1.120 - 2.390
Beta1.55
AnalystsStrong Buy
Price Target3.50 (+189.26%)
Earnings DateAug 5, 2025

About ACCD

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ... [Read more]

Sector Healthcare
IPO Date Jan 30, 1997
Employees 630
Stock Exchange NASDAQ
Ticker Symbol CERS
Full Company Profile

Financial Performance

In 2024, Cerus's revenue was $180.27 million, an increase of 15.29% compared to the previous year's $156.37 million. Losses were -$20.92 million, -44.20% less than in 2023.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for CERS stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 189.26% from the latest price.

Price Target
$3.5
(189.26% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Kevin D. Green - VP of Finance & CFO Vivek K.

5 days ago - Seeking Alpha

Cerus Corporation Announces Second Quarter 2025 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to ad...

5 days ago - Business Wire

Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the st...

19 days ago - Business Wire

Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has been awarded an additional $7.2 million contract amendment by the U.S. Department of Defense (DoD) Indust...

20 days ago - Business Wire

Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. “We are pleased to report that the European regulatory rev...

5 weeks ago - Business Wire

Cerus Corporation Celebrates World Blood Donor Day 2025

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World ...

2 months ago - Business Wire

Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Confe...

2 months ago - Business Wire

Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood ...

2 months ago - Business Wire

Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Sa...

2 months ago - Business Wire

Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Tim Lee - Head of Investor Relations Obi Greenman - President and Chief Executive Officer ...

3 months ago - Seeking Alpha

Cerus Corporation Announces First Quarter 2025 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. “We are off to a strong...

3 months ago - Business Wire

Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock...

4 months ago - Business Wire

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood Sys...

5 months ago - Business Wire

Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS) Q4 2024 Earnings Call February 20, 2025 4:30 PM ET Company Participants Noopur Liffick - Investor Relations Obi Greenman - President and Chief Executive Officer Vivek ...

6 months ago - Seeking Alpha

Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights include: Total reve...

6 months ago - Business Wire

Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of Cerus' management are scheduled to present at the TD Cowen 45th Annual Health Care Conference on Wedn...

6 months ago - Business Wire

Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after t...

6 months ago - Business Wire

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for full-...

7 months ago - Business Wire

Cerus Corporation to Participate in Upcoming Investor Conferences

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to participate in the Stifel 2024 Healthcar...

9 months ago - Business Wire

Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayarama...

10 months ago - Seeking Alpha

Cerus Corporation Announces Third Quarter 2024 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nin...

10 months ago - Business Wire

Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the...

10 months ago - Business Wire

Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) A...

10 months ago - Business Wire

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA contra...

10 months ago - Business Wire

Cerus Corporation (CERS) Q2 2024 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman ...

1 year ago - Seeking Alpha